220640-10-8

Usage

Uses

Used in Pharmaceutical Applications:
(R)-2-AMINO-7-HYDROXYTETRALIN HYBROMIDE is used as an intermediate for the synthesis of complex organic molecules and pharmaceuticals. Its chiral nature, indicated by the (R)-designation, is crucial in drug development, as the compound's stereochemistry can significantly impact its biological activity and efficacy.
Used in Research and Development:
In the field of research and development, (R)-2-AMINO-7-HYDROXYTETRALIN HYBROMIDE serves as a valuable compound for studying the properties and interactions of chiral molecules. Its unique structure allows scientists to explore various aspects of molecular recognition, stereoselectivity, and the influence of stereochemistry on biological activity.
Used in Chemical Synthesis:
(R)-2-AMINO-7-HYDROXYTETRALIN HYBROMIDE is used as a building block in the synthesis of other organic compounds, particularly those with potential applications in the pharmaceutical and chemical industries. Its hydrobromide salt form enhances its solubility, facilitating its use in various chemical reactions and processes.

Upstream product

• 121216-43-1 (2R)-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine 
• 121251-89-6 (R)-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine (S)-mandelate 
• 4133-34-0 7-methoxyl-2-tetralone 
• 4003-89-8 2-amino-7-methoxy-1,2,3,4-tetrahydronaphthalene 
• 3880-78-2 7-Methoxy-1,2,3,4-tetrahydro-(2R)-2-naphthaleneamine hydrochloride 
• 83343-23-1 N-benzyl-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine 

Downstream Products

• 1274816-90-8 N-[(2R)-7-((2-[(cyclopropylcarbonyl)amino]pyridin-4-yl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl]-3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzamide 

Relevant academic research and scientific papers

SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF

This invention provides compounds of formula (I): wherein R1, R1b, R2a, R2b, R2c, and R2d have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

Design and optimization of potent and orally bioavailable tetrahydronaphthalene raf inhibitors

Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.

PREPARATION OF AMINOTETRALIN COMPOUNDS

The present invention relates to synthetic processes for preparation of aminotetralin compounds with kinase inhibitory activity. The invention also provides synthetic intermediates useful in the processes of the invention.